文献速递妇科

晚期卵巢癌间隔减瘤术后残余病灶的新分类以更好区分肿瘤学结局

A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
PubMed 文献 · Am J Obstet Gynecol · 2019-05-10

研究纳入2010年1月至2015年7月接受新辅助化疗后间隔减瘤术的FIGO IIIC/IV期上皮性卵巢/输卵管/原发腹膜癌患者270例,按残余病灶分为完全切除、单解剖部位≤1 cm、多解剖部位≤1 cm和减瘤不足四组,中位无进展生存分别为14、12、10、6个月,中位总生存分别为58、37、26、33个月(均P<.001)。

要点

  • 完全切除者预后最佳,其次为单解剖部位≤1 cm残余病灶者。
  • 多解剖部位≤1 cm残余病灶者生存与减瘤不足者相似。
  • 现行「最佳减瘤」定义未考虑残余病灶总体积和分布。

核心结论

  • 间隔减瘤术后完全切除患者预后最佳,其次为≤1 cm单解剖部位病灶者,而≤1 cm多解剖部位病灶者虽被认为「最佳减瘤」,生存与减瘤不足者相似。

研究设计与样本

  • 收集2010年1月至2015年7月接受间隔减瘤术的FIGO IIIC和IV期上皮性卵巢癌患者的病历资料,共270例。

主要发现

  • 270例中完全切除173例(64.1%),单解剖部位≤1 cm残余34例(12.6%),多解剖部位≤1 cm残余47例(17.4%),减瘤不足16例(5.9%)。
  • 四组中位无进展生存分别为14、12、10、6个月(P<.001)。
  • 四组中位总生存分别为58、37、26、33个月(P<.001)。

关键数值与推荐

  • 当前「最佳」减瘤定义为最大病灶直径≤1.0 cm,不考虑病灶总体积。
  • 未完全切除但残余≤1 cm者,以残余病灶解剖部位数(单处 vs 多处)作为残余病灶体积的替代指标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complete surgical resection affords the best prognosis at the time of interval debulking surgery. When complete surgical resection is unachievable, optimal residual disease is considered the next best alternative. Despite contradicting evidence on the survival benefit of interval debulking surgery if macroscopic residual disease remains, the current definition of "optimal" in patients undergoing interval debulking surgery is defined as largest diameter of disease measuring ≤1.0 cm, independent of the total volume of disease. OBJECTIVE: To examine the relationship between volume and anatomic distribution of residual disease and oncologic outcomes among patients with advanced-stage epithelial ovarian/fallopian tube/primary peritoneal carcinoma undergoing neoadjuvant chemotherapy then interval debulking surgery. For patients who did not undergo a complete surgical resection, a surrogate for volume of residual disease was used to assess oncologic outcomes. STUDY DESIGN: Patient demographics, operative characteristics, anatomic site of residual disease, and outcome data were collected from medical records of patients with International Federation of Gynecology and Obstetrics stage IIIC and IV epithelial ovarian cancer undergoing interval debulking surgery from January 2010 to July 2015. Among patients who did not undergo complete surgical resection but had ≤1 cm of residual disease, the number of anatomic sites (single location vs multiple locations) with residual disease was used as a surrogate for volume of residual disease. The effect of residual disease volume on progression-free survival and overall survival was evaluated. RESULTS: Of 270 patients undergoing interval debulking surgery, 173 (64.1%) had complete surgical resection, 34 (12.6%) had ≤1 cm of residual disease in a single anatomic location, 47 (17.4%) had ≤1 cm of residual disease in multiple anatomic locations, and 16 (5.9%) were suboptimally debulked. Median progression-free survival for each group was 14, 12, 10, and 6 months, respectively (P<.001). Median overall survival for each group was: 58, 37, 26, and 33 months, respectively (P<.001). CONCLUSION: Following interval debulking surgery, patients with complete surgical resection have the best prognosis, followed by patients with ≤1 cm single-anatomic location disease. In contrast, despite being considered "optimally debulked," patients with ≤1 cm multiple-anatomic location disease have a survival similar to suboptimally debulked patients.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Manning-Geist BL, Hicks-Courant K, Gockley AA, et al. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol. 2019. PMID: 31082382. doi:10.1016/j.ajog.2019.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。